Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Daily Feed
  • IR Room
  • RESEARCH
  • Disclosures
    • Semiconductors
    • Energy
    • Robotics
    • Bio & Healthcare
  • Toggle search form

[Disclosure] Celltrion (068270) Announces Amended Listing Schedule on KRX Following Reduction of 9.11 Million Common Shares via Share Retirement

Posted on April 8, 2026July 14, 2026 By K-STOCK Editor No Comments on [Disclosure] Celltrion (068270) Announces Amended Listing Schedule on KRX Following Reduction of 9.11 Million Common Shares via Share Retirement

Source: Financial Supervisory Service Data Analysis, Retrieval and Transfer System (DART) / 2026-04-08

Disclosure Type: Amendment of Share Listing (Share Retirement)

💡 3-Second Summary

Due to a share retirement, Celltrion’s total outstanding common shares will decrease by 9,110,000 shares, moving from 231,048,261 shares to 221,938,261 shares, with the amended listing scheduled to take effect on the KRX on April 13, 2026.

📊 1. [Key Disclosure Details & Major Figures Summary]

  • Target Security: Celltrion Common Stock (ISIN: KR7068270008 / Short Code: A068270)
  • Adjustment in Number of Shares (Before ➡️ After):
    • Pre-Amendment Volume: 231,048,261 Common Shares
    • Post-Amendment Volume: 221,938,261 Common Shares
    • Net Change (Amended Share Count): -9,110,000 shares
  • Amount per Share (Par Value): KRW 1,000
  • Timeline Information:
    • Date of Issuance: April 1, 2026
    • Amended Listing Date: April 13, 2026
  • Dividend & Settlement Details: Dividend accrual base date is January 1, 2026 / Fiscal year-end is the last day of December
  • Reason for Amendment: Share retirement
  • Sector Code: 03-21-01

📈 2. [Expert Perspective: What This Means for Investors]

  • Confirmation of Technical Amended Listing Date: This filing functions as an official notification establishing the exact date (April 13, 2026) when the physical reduction of 9,110,000 common shares will be processed in the exchange trading systems. The share retirement, which became effective on April 1, 2026, completes its administrative protocol with this exchange registration.
  • Quantitative Change in Outstanding Share Count: Market participants can confirm the quantitative fact that Celltrion’s registered outstanding shares will decrease from approximately 231.05 million shares to 221.94 million shares. The disclosure remains strictly focused on this volume shift and does not state downstream financial results or specify if any alterations occur to the company’s capital stock.
  • Boundaries of Interpretation: An amended listing document is a technical report reflecting that market databases will formally display the updated share count beginning April 13, 2026. Any potential impact this quantitative reduction might have on market pricing or broader financial variables is not covered by this disclosure and should be evaluated through verified upcoming quarterly statements.

📝 Editor’s Comment (by K-STOCK Editor)

This amended listing filing delivers the objective metric that 9.11 million common shares will contract under the cause of share retirement, with the changes reflecting on April 13. The document is strictly an administrative report of a numerical update and leaves out any discussion regarding corporate intentions, impacts on the capital stock, or per-share financial developments. Consequently, readers should look exclusively at the verified data parameters without projecting speculative downstream financial impacts, keeping their focus entirely on the physical reduction of the outstanding share base.

📢 Disclaimer & Sources

Source: This content has been newly structured and written based on official data submitted to the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).

Investment Risk Warning: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: For compliance inquiries or copyright-related requests, please contact ksb220805@gmail.com.

🐂
BULLS
VS
🐻
BEARS

🔥 Bulls vs Bears, drop your analysis in the comments!

Disclosures, Bio & Healthcare

Post navigation

Previous Post: [Disclosure] Alteogen (196170) to Host Domestic IR in Yeouido, Signaling Major Updates on Bio Platform & Pipelines
Next Post: [Disclosure] Samsung Biologics (207940) Pre-Announces Q1 2026 Financial Results Publication for April 22

Related Posts

[Disclosure] Alteogen(196170) to Acquire 859,018 New Shares of Altos Biologics via Subsidiary Merger (No Additional Capital Outflow) Disclosures
[Disclosure] Samsung Biologics (207940) Sets Evaluated Price at KRW 1,221,000 for Relisting Following Corporate Division Bio & Healthcare
[Disclosure] Samsung Biologics (207940) Discloses Additional CMO Contract Worth KRW 56.7B with European Pharmaceutical Company Disclosures
[Disclosure] Alteogen(196170) Changes CEO from Soon Jae Park to Tae Yeon Jeon Disclosures
[Disclosure]  SK Hynix (000660) Announces Quarterly Dividend of 375 KRW per Share… Total Payout Approximately 265.8 Billion KRW Semiconductors
[Disclosure] Samsung Biologics (207940) Amends European Pharma Contract Value Upward to KRW 349.9B Disclosures

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Celltrion (068270) Submits Application to Modify Phase 3 Clinical Trial Plan for ‘CT-P44’ (Darzalex Biosimilar) in EuropeJuly 14, 2026
  • [Disclosure] Hanmi Semiconductor (042700) Reports Q2 2026 Operating Profit of KRW 130.3B… A Explosive 1,441.4% QoQ SurgeJuly 14, 2026
  • [Disclosure] SK Square (402340) Discloses Subsidiary SK Hynix’s Successful ADR Listing on the U.S. NASDAQ MarketJuly 13, 2026
  • [Disclosure] SK Hynix (000660) Completes Listing of ADRs (American Depositary Receipts) on the U.S. NASDAQ MarketJuly 13, 2026
  • [Disclosure] Samsung Electronics (005930) to Dispose of KRW 322.8B Worth of Treasury Shares for Executive BonusesJuly 13, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme